ISO 9001 (Quality)

Qualio

Life sciences startups and scale-ups (10–500 employees) in medical device, pharmaceutical, biotech, and digital health — organizations building their first FDA-compliant QMS and needing deployment in weeks, not months.

Try this tool
AiGreenTools Score
71 / 100
Rating G2 / Capterra
4.4
★★★★☆
out of 5 · G2 / Capterra
Pricing
paid

AiGreenTools Score breakdown

How is this score calculated?
Sustainability Impact 5 / 20
Features & Capabilities 15 / 20
Value for Money 17 / 20
Ease of Use 19 / 20
Trust & Maturity 15 / 20

Reviewed by the AiGreenTools Editorial Team · Last Updated: June 2026

Founded ~2015, life sciences-exclusive QMS
Best for Life sciences startups and scale-ups (10–500 employees) — medical device, pharma, biotech, digital health — building first FDA-compliant QMS
Pricing From ~EUR 25,000/year — 3-year minimum commitment (~EUR 75,000 total)
AI Classification AI Enhanced (Qualio AI — document change summaries, compliance gap analysis)
Key Standards FDA 21 CFR Part 11, ISO 13485, EU MDR, MDSAP, GxP, ICH Q10, QMSR (eff. Feb 2026)
Maturity Stage Stage 2–3
Key Differentiator 99% of customers use pre-validation package — market entry timelines cut from 9 months to 3–4 months

Picture the Life Sciences Company Qualio Is Built For

A 35-person medical device startup, Series A funded, three engineers and a Quality Assurance Director hired six months ago. The QA Director inherited a document management situation: product specifications in Google Drive, training records in an Excel matrix, deviation reports in Jira tickets, approval signatures through DocuSign, and SOPs in SharePoint folders where version control requires trusting that everyone opens the most recently dated file.

A notified body audit is scheduled in 14 weeks for CE marking. The FDA pre-market submission is planned for Q3. The QA Director has two choices: build a validated eQMS from scratch using an enterprise platform that requires 6 months of implementation before the first controlled document exists; or find a platform that can have a compliant, pre-validated QMS operational in 2 weeks and grow with the company through commercialization.

That second choice is what Qualio was built for. The market between “no QMS” and “enterprise MasterControl” is where most life sciences startups actually operate — and where Qualio specifically positioned itself when it recognized that FDA compliance should be accessible to a 35-person company on the same quality standard as a 3,500-person pharmaceutical manufacturer.

What Is Qualio — and What Makes It Different From Enterprise QMS Platforms?

Quick Answer: Qualio is a cloud-native QMS built exclusively for life sciences companies — medical device, pharma, biotech, and digital health. It deploys in weeks using pre-built life sciences workflows and a pre-validation package used by 99% of customers. Pricing starts at approximately EUR 25,000/year with a 3-year minimum commitment. It is the right platform for organizations building their first FDA-compliant QMS without enterprise implementation resources.

What Qualio covers in a single deployment:

  • Document Control: Version history, approval routing, PDF rendering, 21 CFR Part 11-compliant electronic signatures
  • Training Management: Automatic assignments on document release, competency tracking, training matrix visibility
  • CAPA: Root cause analysis, corrective action, effectiveness verification — full lifecycle tracking
  • Change Control: Documented impact assessments and multi-level approval chains
  • Design Controls: DHF management, risk-requirements traceability — aligned with ISO 13485 Clause 7.3 and QMSR
  • Audit Management: Configurable checklists, finding tracking, closure verification
  • Supplier Management: Qualification status, approved supplier list maintenance
  • Complaint Handling: Automated response workflows linking to CAPA

What Does “Pre-Validated QMS” Mean — and Why Does Only 1% Self-Validate?

Software validation in GxP environments is a regulatory obligation under 21 CFR Part 11 and ISO 13485. Any computerized quality system must be validated to demonstrate reliable, consistent performance — with documented installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ) protocols. In a traditional QMS deployment, this validation project requires quality IT resources, protocol writing, protocol execution, and review — a weeks-long exercise before the first controlled document can be managed in the validated system.

Qualio’s pre-validation package is the reason this matters. The package provides Qualio-specific IQ/OQ/PQ documentation pre-written, pre-executed, and aligned with FDA Computer Software Assurance (CSA) guidance (effective September 2025) and GAMP 5 principles. Organizations that accept the pre-validation package — 99% of Qualio customers — skip the validation project entirely and begin managing controlled documents in a compliant, validated QMS within days of platform setup.

This is not a shortcut around compliance. The pre-validation package produces the same documented evidence of system validation that a custom validation project would produce. The difference is who does the work: Qualio’s quality team, with platform expertise and validated-state documentation, versus the customer’s quality team, which typically lacks platform-specific validation expertise at startup stage.

Qualio vs. MasterControl — When Does Each Apply?

Dimension Qualio MasterControl
Typical organization 10–500 employees, startup to early commercial 500+ employees, enterprise, multi-site
Deployment timeline 2–4 weeks to first compliant QMS Months to a year (multi-site enterprise)
Validation approach Pre-validation package — 99% of customers Patented VxT — delta validation on updates
Configuration model Opinionated life sciences workflows — fast, less flexible Connected modules — deep, more configuration overhead
Manufacturing execution No maintenance module — no eBR MasterControl Mx — eBR, MES capabilities
Pricing entry ~EUR 25,000/year, 3-year commitment ~$25,000+/year, enterprise custom
Best for First QMS, FDA submission preparation, clinical stage Manufacturing scale, complex CAPA, multi-site

How Does Qualio Address the FDA QMSR — Effective February 2, 2026?

The FDA QMSR (Quality Management System Regulation, effective February 2, 2026) replaced 21 CFR Part 820 for medical device manufacturers by incorporating ISO 13485:2016 by reference. For Qualio customers, this creates compliance requirements in several areas where ISO 13485 is more prescriptive than the previous Part 820: risk management integration (ISO 14971 alignment required), design change control (Clause 7.3 specific requirements), and supplier evaluation (Clause 7.4 documentation requirements).

Qualio’s existing ISO 13485-aligned workflows address these requirements without requiring platform revalidation — the platform’s pre-validated state covers the ISO 13485 process requirements that QMSR now mandates. For Qualio customers in the medical device space who maintained Part 820-only documentation previously, the primary action item is reviewing their existing quality procedures against ISO 13485 clause requirements and updating SOPs accordingly — the platform infrastructure itself handles the compliance posture.

For pharmaceutical and biotech customers covered by 21 CFR Parts 210/211 rather than QMSR, Qualio’s 21 CFR Part 11 and GxP compliance requirements are unchanged. For EHS quality context alongside QMS, see our profiles on Intelex and ETQ Reliance. For ISO 45001 management system context, see our ISO 45001 guide.

The Developer and Product Team Integration — Why It Matters for Biotech and SaMD

Life sciences startups are frequently engineering-led organizations where the quality system must coexist with product development workflows that run in Jira, Asana, GitHub, and Benchling — not in quality management platforms. Qualio’s integration approach addresses this organizational reality directly.

Key integrations and their operational value:

  • Jira: Links CAPA records to software development tickets — when a quality event requires a software fix, the traceability between quality system and development pipeline is maintained without manual cross-referencing
  • Benchling: Connects lab notebook and molecular biology records to Qualio quality documentation — enabling regulatory evidence links between experimental data and quality SOPs for biotech manufacturing processes
  • Azure DevOps: Serves SaMD (software as a medical device) companies where software quality records must link to CI/CD pipeline artifacts for IEC 62304 compliance
  • Salesforce: Connects customer complaints to Qualio quality events — enabling post-market surveillance workflows aligned with EU MDR and FDA complaint handling requirements
  • Asana: Project management integration for CAPA and change control action tracking outside the QMS workflow

Who Should Not Choose Qualio?

Enterprise pharmaceutical organizations with 500+ employees, multi-site operations, complex CAPA programs across multiple product lines, and manufacturing execution requirements (electronic batch records, MES integration) should evaluate MasterControl. Qualio’s opinionated model and configuration constraints become limiting as organizational complexity grows beyond the startup and early-scale stage.

Medical device manufacturers with significant equipment calibration, maintenance, and asset management requirements embedded in their quality system will find Qualio’s absence of a maintenance module a meaningful gap. An asset management or CMMS tool must be deployed alongside Qualio to cover equipment-linked quality records — adding integration complexity that MasterControl or ETQ Reliance avoid through native asset management modules.

Organizations needing highly customized workflows that deviate significantly from standard life sciences quality processes — complex multi-tier approval chains, bespoke deviation classification systems, or regulatory submission management beyond standard quality events — will encounter Qualio’s configurability ceiling before MasterControl or ETQ Reliance’s more flexible architectures. The platform is opinionated precisely because that opinion enables speed; customization requests reveal the boundaries of that opinion.

The Verdict on Qualio

Qualio is the right QMS for the life sciences startup or scale-up that is not yet ready for MasterControl’s enterprise complexity and not willing to manage quality in SharePoint and Excel until it is. The pre-validation package, the life sciences-native workflows, the Jira and Benchling integrations, and the deployment timeline measured in weeks rather than months serve a specific and substantial organizational profile: the company with an FDA deadline, a small quality team, and a budget that requires proportionate technology investment. When that company reaches manufacturing scale, multi-site complexity, and CAPA volumes that exceed Qualio’s model — the upgrade path exists, and it runs through MasterControl or Veeva Vault QMS. Qualio is the platform that gets organizations to that upgrade threshold with their FDA compliance intact.

Qualio screenshot

Key Information

Best For
Life sciences startups and scale-ups (10–500 employees) in medical device, pharmaceutical, biotech, and digital health — organizations building their first FDA-compliant QMS and needing deployment in weeks, not months.
Year Founded
2012

Key Features

  • ✓ Pre-Validated QMS — 99% of Customers Skip Self-Validation Qualio's most operationally significant differentiator is not a feature — it is a deployment fact: only 1% of Qualio customers perform self-validation of the platform. The remaining 99% use Qualio's pre-validation package, which provides the documented IQ/OQ/PQ evidence required by FDA and ISO 13485 for electronic quality systems. For a 30-person medical device company whose quality lead is also managing regulatory affairs, supply quality, and audit preparation, the elimination of the validation project removes the primary barrier to QMS deployment. In the enterprise QMS world, software validation is a weeks-long exercise. In Qualio, it is a step in a 2-week onboarding process. The resulting quality system is fully 21 CFR Part 11 compliant with an audit trail, electronic signatures with complete provenance, and role-based access controls — the same regulatory requirements that MasterControl satisfies through its VxT tooling, delivered without the VxT complexity at growth-stage scale.
  • ✓ Life Sciences-Native Workflows — Document Control, CAPA, Design Controls Qualio provides purpose-built workflows for the quality processes FDA inspectors examine in life sciences: document control with version history, approval routing, and PDF rendering with electronic signatures compliant with 21 CFR Part 11; CAPA management from initial observation through root cause analysis, corrective action, and effectiveness verification; change control with documented impact assessments and approval chains; design controls aligned with 21 CFR Part 820 and ISO 13485 Clause 7.3 for medical device development — including Design History File (DHF) management and risk-requirements traceability; audit management with configurable checklists and finding tracking; and supplier management with qualification status and approved supplier list maintenance. The QMSR (effective February 2, 2026), which incorporates ISO 13485 by reference, is addressed through Qualio's existing ISO 13485-aligned workflows without requiring platform revalidation.
  • ✓ Developer and Product Team Integration — Jira, Asana, Benchling, Azure Qualio's integration ecosystem reflects the organizational reality of life sciences startups: quality management does not exist separately from product development. The Jira integration connects quality events to software development tickets — when a CAPA in Qualio requires a software change, it links to the corresponding Jira issue, maintaining traceability between quality system and product development workflow. The Benchling integration connects Qualio to lab notebook and molecular biology data — enabling regulatory evidence links between experimental records and quality documentation without manual data transfer. Azure DevOps integration serves software-as-medical-device (SaMD) companies where software quality records must link to development pipeline artifacts. The Salesforce integration supports complaint management workflows where customer complaints initiate Qualio quality events. For digital health and SaMD companies, this integration breadth is the capability that makes Qualio the platform of choice in their organizational environment.

Pros & Cons

Strengths

  • The deployment speed is Qualio's most operationally significant competitive advantage for life sciences startups. A company that begins a Qualio deployment in January can have a validated, FDA-compliant QMS operational by February — with controlled documents, training records, CAPA workflows, and electronic signatures meeting 21 CFR Part 11 requirements. This 2–4 week timeline is structurally impossible on enterprise QMS platforms requiring months of configuration and validation. For a startup approaching a Series B with an FDA pre-market submission timeline, the ability to demonstrate a functioning quality management system with documented audit trails matters financially — and Qualio is the fastest path to that demonstration.
  • The pre-validation package — used by 99% of customers — eliminates the validation project that is the primary barrier to QMS adoption for small life sciences teams. Qualification protocol writing, execution, and documentation in a pharmaceutical environment typically requires a quality IT resource that most 30-person biotechs do not have. Qualio's approach — providing pre-written, platform-specific IQ/OQ/PQ documentation as part of standard deployment — is the single most consequential difference between Qualio and every enterprise QMS platform for organizations at the startup and early-scale stage.
  • The user experience for non-quality team members — the clinical researchers, lab scientists, and manufacturing operators who need to acknowledge documents, complete training, and log observations without extensive QMS expertise — is consistently cited in Qualio reviews as the adoption differentiator. Adoption rates for non-quality users are better than average for QMS platforms of any category, reflecting Qualio's design philosophy that a QMS must be usable by the people who are not quality professionals if it is to function as an organizational quality system rather than a compliance documentation repository managed by a single quality team.

Weaknesses

  • Qualio's opinionated workflow model — the feature that enables rapid deployment — creates configuration constraints that organizations encounter as they scale. Document navigation without a folder structure requires knowing document titles or tags to locate specific records, which becomes operationally challenging in large document libraries. The training module has specific limitations for on-the-job training (OJT) documentation that some GMP organizations find require workarounds. Reporting customization is more limited than enterprise QMS platforms — organizations that need complex analytical dashboards on CAPA performance, deviation trending, or supplier quality metrics across complex organizational hierarchies typically supplement Qualio with external BI tools. The platform is opinionated; it accelerates implementation for organizations that adopt its model and creates friction for those that need to replicate existing non-standard quality processes digitally.
  • The pricing model combines a high entry price (~EUR 25,000/year) with a 3-year minimum commitment, producing a total initial commitment of approximately EUR 75,000 before implementation costs and additional user seats. Setup fees of EUR 8,000–20,000 add to first-year cost. For a pre-revenue startup managing a Series A budget, this pricing requires investor alignment before QMS selection — the platform's capabilities justify the investment for organizations approaching FDA submission, but the minimum commitment structure requires financial planning that bootstrap- stage companies may find constraining relative to lighter-weight QMS alternatives at lower price points.
  • Qualio does not have a maintenance module — the platform manages quality events, document control, and training but does not track physical asset maintenance, calibration scheduling with equipment-linked records, or work orders for manufacturing equipment. For medical device manufacturers where device production requires equipment calibration records, maintenance logs linked to quality events, and asset-level traceability in the quality system — Qualio requires supplementing with a CMMS or asset management tool. This is not a limitation for pharma, biotech, or SaMD companies where the quality system's relationship with physical equipment is less central, but it is a meaningful gap for manufacturers of hardware medical devices.

Frequently Asked Questions

Categories ISO 9001 (Quality)

Tags biotech change-control cro eu-mdr FDA iso-13485 life-sciences medical-devices Pharma qms

© 2026 AiGreenTools. All rights reserved.